Africa’s first participation in a COVID-19 vaccine trial has begun as volunteers received injections, while officials say the continent of 1.3 billion people cannot be left behind
JOHANNESBURG — Africa’s first participation in a COVID-19 vaccine trial started Wednesday as nervous volunteers received injections, while officials said the continent of 1.3 billion people cannot be left behind.
The large-scale trial of the vaccine developed at the University of Oxford in Britain is being conducted in South Africa, Britain and Brazil. South Africa has nearly one-third of Africa’s confirmed cases with more than 106,000, including more than 2,100 deaths. The country late Tuesday reported its biggest one-day death toll of 111.
“I feel a little bit scared but I want to know what is going on with this vaccine so that I can tell my friends and others what is going on with the study,” one of the vaccine trial volunteers, Junior Mhlongo, said in Johannesburg.
The African continent now has nearly 325,000 cases as countries loosen restrictions under economic pressure from citizens who say they have to feed their families. Shortages of testing materials and medical supplies remain a problem as Africa could become the world’s next hot spot.
The pandemic was delayed in Africa “but is picking up speed very quickly,” the Africa Centers for Disease Control and Prevention chief John Nkengasong said Wednesday, with a steep increase in the number of cases and deaths.
“Unless we act now, Africa is at risk of being left behind on the global vaccine,” he warned a continental discussion and urged that local manufacturing and scientific expertise play a key role.
Cameroon, Uganda, Tanzania, Kenya and South Africa all have highly developed clinical trial capabilities, said Salim Abdool Karim, chair of South Africa’s ministerial advisory committee for COVID-19.
Many other sub-Saharan African countries also have clinical trial capacity, said Daniel Bausch, director of the UK Public Health Rapid Support Team.
- Good news — scientists discovered a property of coronavirus that will make a long-term vaccine possible
“We’re not only needing but capable of participating” as the world races for a vaccine, South Africa’s Health Minister Zweli Mkhize said.
African leaders have been outspoken about the continent being elbowed out in the intense global competition for medical supplies in this pandemic, as well as what the World Health Organization’s Africa chief, Matshidiso Moeti, called the “distortion of the global market for key items.”
WHO chief Tedros Adhanom Ghebreyesus urged that the initial supply of any COVID-19 vaccine be deployed where it’s most needed, rather than based on the “ability to pay.”
Tedros also announced that as of this week, all 54 of Africa’s countries now have the lab capacity to test for the coronavirus.
In February, just two African nations could test for the virus. The continent’s first virus case was reported on Feb. 14.